Genetic Testing in Hypertrophic Cardiomyopathy
Catherine G. Ireland(Brigham and Women's Hospital), Carolyn Y. Ho(Brigham and Women's Hospital)
Cited by 33
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations
|Cardiovascular Research|2014|125
Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy
|Circulation|2023|87
Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis
|Journal of the American College of Cardiology|2025|40
Exercise right ventricular ejection fraction predicts right ventricular contractile reserve
|The Journal of Heart and Lung Transplantation|2021|34